# CNS Pharmaceuticals, Inc.: financial statements, quarterly

CNSP · Nasdaq · CIK 1729427 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cnsp.md) · [Financials](/companies/cnsp/financials.md) · [Filings](/companies/cnsp/filings.md) · [Insiders](/companies/cnsp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cnsp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [3,411](/filings/0001683168-24-008125.md) | [4,272 d](/filings/0001683168-25-002139.md) | [2,430](/filings/0001683168-25-003733.md) | [1,117](/filings/0001683168-25-006162.md) | [4,245](/filings/0001683168-25-008466.md) | [1,498 d](/filings/0001683168-26-002550.md) | [3,243](/filings/0001683168-26-003847.md) | [1,167](/filings/0001683168-26-006224.md) | [2,197](/filings/0001683168-25-008466.md) | [3,165 d](/filings/0001683168-26-002550.md) | [3,544](/filings/0001683168-26-003847.md) | [1,201](/filings/0001683168-26-006224.md) |
| Operating income | $k | [(4,534)](/filings/0001683168-24-008125.md) | [(5,379) d](/filings/0001683168-25-002139.md) | [(3,545)](/filings/0001683168-25-003733.md) | [(2,528)](/filings/0001683168-25-006162.md) | [(5,629)](/filings/0001683168-25-008466.md) | [(3,200) d](/filings/0001683168-26-002550.md) | [(4,338)](/filings/0001683168-26-003847.md) | [(2,409)](/filings/0001683168-26-006224.md) | [(3,253)](/filings/0001683168-25-008466.md) | [(5,986) d](/filings/0001683168-26-002550.md) | [(4,975)](/filings/0001683168-26-003847.md) | [(2,700)](/filings/0001683168-26-006224.md) |
| Interest expense | $k | [1.8](/filings/0001683168-23-008144.md) | [2.9 d](/filings/0001683168-24-002032.md) | [6.6](/filings/0001683168-24-003531.md) | [4.5](/filings/0001683168-25-006162.md) | [2.3](/filings/0001683168-25-008466.md) | [2.8 d](/filings/0001683168-26-002550.md) | [6.2](/filings/0001683168-26-003847.md) | [4.0](/filings/0001683168-26-006224.md) | [2.1](/filings/0001683168-25-008466.md) | [2.7 d](/filings/0001683168-26-002550.md) | [6.1](/filings/0001683168-26-003847.md) | [4.0](/filings/0001683168-26-006224.md) |
| Net income | $k | [(4,523)](/filings/0001683168-24-008125.md) | [(5,375) d](/filings/0001683168-25-002139.md) | [(3,545)](/filings/0001683168-25-008466.md) | [(2,531)](/filings/0001683168-25-008466.md) | [(5,606)](/filings/0001683168-25-008466.md) | [(3,176) d](/filings/0001683168-26-002550.md) | [(4,301)](/filings/0001683168-26-006224.md) | [(2,375)](/filings/0001683168-26-006224.md) | [(3,218)](/filings/0001683168-25-008466.md) | [(5,956) d](/filings/0001683168-26-002550.md) | [(4,937)](/filings/0001683168-26-006224.md) | [(2,588)](/filings/0001683168-26-006224.md) |
| Diluted EPS | $ per share | [(54.14)](/filings/0001683168-24-008125.md) | not reported | [(1020.48)](/filings/0001683168-25-003733.md) | [(4049.20)](/filings/0001683168-25-006162.md) | [(153.20)](/filings/0001683168-25-008466.md) | not reported | [(18.93)](/filings/0001683168-26-003847.md) | [(6.42)](/filings/0001683168-26-006224.md) | [(5.76)](/filings/0001683168-25-008466.md) | not reported | [(7.30)](/filings/0001683168-26-003847.md) | [(0.38)](/filings/0001683168-26-006224.md) |
| Basic EPS | $ per share | [(54.14)](/filings/0001683168-24-008125.md) | not reported | [(1020.48)](/filings/0001683168-25-003733.md) | [(4049.20)](/filings/0001683168-25-006162.md) | [(153.20)](/filings/0001683168-25-008466.md) | not reported | [(18.93)](/filings/0001683168-26-003847.md) | [(6.42)](/filings/0001683168-26-006224.md) | [(5.76)](/filings/0001683168-25-008466.md) | not reported | [(7.30)](/filings/0001683168-26-003847.md) | [(0.38)](/filings/0001683168-26-006224.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.9](/filings/0001683168-23-008144.md) | [0.5](/filings/0001683168-25-002139.md) | [0.8](/filings/0001683168-24-003531.md) | [1.5](/filings/0001683168-24-005711.md) | [7.0](/filings/0001683168-24-008125.md) | [6.5](/filings/0001683168-26-002550.md) | [13.0](/filings/0001683168-25-003733.md) | [12.1](/filings/0001683168-25-006162.md) | [9.9](/filings/0001683168-25-008466.md) | [7.2](/filings/0001683168-26-006224.md) | [3.0](/filings/0001683168-26-003847.md) | [20.0](/filings/0001683168-26-006224.md) |
| Current assets | $m | [2.1](/filings/0001683168-23-008144.md) | [1.6](/filings/0001683168-25-002139.md) | [1.6](/filings/0001683168-24-003531.md) | [2.1](/filings/0001683168-24-005711.md) | [7.4](/filings/0001683168-24-008125.md) | [8.7](/filings/0001683168-26-002550.md) | [13.7](/filings/0001683168-25-003733.md) | [14.1](/filings/0001683168-25-006162.md) | [11.4](/filings/0001683168-25-008466.md) | [8.1](/filings/0001683168-26-006224.md) | [4.1](/filings/0001683168-26-003847.md) | [21.9](/filings/0001683168-26-006224.md) |
| Total assets | $m | [2.3](/filings/0001683168-23-008144.md) | [1.7](/filings/0001683168-25-002139.md) | [1.7](/filings/0001683168-24-003531.md) | [2.5](/filings/0001683168-24-005711.md) | [7.4](/filings/0001683168-24-008125.md) | [8.7](/filings/0001683168-26-002550.md) | [13.7](/filings/0001683168-25-003733.md) | [14.5](/filings/0001683168-25-006162.md) | [11.9](/filings/0001683168-25-008466.md) | [8.6](/filings/0001683168-26-006224.md) | [4.7](/filings/0001683168-26-003847.md) | [21.9](/filings/0001683168-26-006224.md) |
| Current liabilities | $m | [4.1](/filings/0001683168-23-008144.md) | [6.1](/filings/0001683168-25-002139.md) | [6.1](/filings/0001683168-24-003531.md) | [6.8](/filings/0001683168-24-005711.md) | [4.1](/filings/0001683168-24-008125.md) | [2.5](/filings/0001683168-26-002550.md) | [2.8](/filings/0001683168-25-003733.md) | [1.4](/filings/0001683168-25-006162.md) | [2.0](/filings/0001683168-25-008466.md) | [4.1](/filings/0001683168-26-006224.md) | [4.6](/filings/0001683168-26-003847.md) | [3.7](/filings/0001683168-26-006224.md) |
| Total liabilities | $m | [4.1](/filings/0001683168-23-008144.md) | [6.1](/filings/0001683168-25-002139.md) | [6.1](/filings/0001683168-24-003531.md) | [6.8](/filings/0001683168-24-005711.md) | [4.1](/filings/0001683168-24-008125.md) | [2.5](/filings/0001683168-26-002550.md) | [2.8](/filings/0001683168-25-003733.md) | [1.4](/filings/0001683168-25-006162.md) | [2.0](/filings/0001683168-25-008466.md) | [4.1](/filings/0001683168-26-006224.md) | [4.6](/filings/0001683168-26-003847.md) | [3.7](/filings/0001683168-26-006224.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(1.7)](/filings/0001683168-24-008125.md) | [(4.4)](/filings/0001683168-26-002550.md) | [(4.4)](/filings/0001683168-25-008466.md) | [(4.3)](/filings/0001683168-25-008466.md) | [3.4](/filings/0001683168-25-008466.md) | [6.2](/filings/0001683168-26-006224.md) | [11.0](/filings/0001683168-26-006224.md) | [13.1](/filings/0001683168-26-006224.md) | [9.9](/filings/0001683168-25-008466.md) | [4.5](/filings/0001683168-26-006224.md) | [0.1](/filings/0001683168-26-006224.md) | [18.2](/filings/0001683168-26-006224.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,376) d](/filings/0001683168-24-008125.md) | [(2,536) d](/filings/0001683168-25-002139.md) | [(3,192)](/filings/0001683168-25-003733.md) | [(1,650) d](/filings/0001683168-25-006162.md) | [(6,800) d](/filings/0001683168-25-008466.md) | [(5,471) d](/filings/0001683168-26-002550.md) | [(3,242)](/filings/0001683168-26-003847.md) | [(5,344) d](/filings/0001683168-26-006224.md) | [(2,173) d](/filings/0001683168-25-008466.md) | [(3,052) d](/filings/0001683168-26-002550.md) | [(4,649)](/filings/0001683168-26-003847.md) | [(3,539) d](/filings/0001683168-26-006224.md) |
| Capital expenditure | $k | [1.7 d](/filings/0001683168-24-008125.md) | [2.2 d](/filings/0001683168-25-002139.md) | not reported | not reported | not reported | [4.2 d](/filings/0001683168-26-002550.md) | [0.0](/filings/0001683168-26-003847.md) | [0.0 d](/filings/0001683168-26-006224.md) | not reported | not reported | [6.2](/filings/0001683168-26-003847.md) | [3.8 d](/filings/0001683168-26-006224.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [1,334](/filings/0001683168-23-008144.md) | [1,906](/filings/0001683168-24-003531.md) | [77.5](/filings/0001683168-24-005711.md) | [83.5](/filings/0001683168-24-008125.md) | [3.5](/filings/0001683168-25-003733.md) | [0.6](/filings/0001683168-25-006162.md) | [36.6](/filings/0001683168-25-008466.md) | [227](/filings/0001683168-26-003847.md) | [370](/filings/0001683168-26-006224.md) | [559](/filings/0001683168-25-008466.md) | [676](/filings/0001683168-26-003847.md) | [6,838](/filings/0001683168-26-006224.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,461,449 at 2026-08-11, from the cover of the [10-Q filed 2026-08-12](/filings/0001683168-26-006224.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.